The World Health Organization said Monday that it will temporarily drop hydroxychloroquine — the malaria drug U.S. President Trump says he is taking — from its global study into experimental COVID-19 treatments, saying that its experts need to review all available evidence to date.
In a press briefing, WHO director-general Tedros Adhanom Ghebreyesus said that in light of a paper published last week in the Lancet that showed people taking hydroxychloroquine were at higher risk of death and heart problems, there would be “a temporary pause” on the hydroxychloroquine arm of its global clinical trial.
“This concern relates to the use of hydroxychloroquine and chloroquine in COVID-19,” Tedros said, adding that the drugs are approved treatments for people with malaria or autoimmune diseases. Other treatments in the trial, including the experimental drug remdesivir and an HIV combination therapy, are still being tested.
Community Interviews with Moose FM
Story continues below advertisement
Tedros said the executive group behind WHO’s global “Solidarity” trial met on Saturday and decided to conduct a comprehensive review of all available data on hydroxychloroquine and that its use in the trial would be suspended for now.
1:54Coronavirus outbreak: Study finds hydroxychloroquine may be tied to higher fatality risk for COVID-19 patients
Coronavirus outbreak: Study finds hydroxychloroquine may be tied to higher fatality risk for COVID-19 patients